Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Not Recruiting

Trial ID: NCT01874054


The purpose of this study is to assess safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is an open-label, 2-stage study designed to determine the recommended dose level of bendamustine in combination with brentuximab vedotin. The study will assess the safety profile of the combination treatment and determine what proportion of patients achieve a complete remission.

Official Title

A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

Stanford Investigator(s)

Ranjana Advani
Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma

Hans-Christoph Becker, MD, FSABI, FSCCT

Clinical Professor, Radiology


Inclusion Criteria:

   - Histopathological diagnosis of classical Hodgkin lymphoma

   - Failed standard front-line therapy

   - Measurable disease of at least 1.5 cm as documented by radiographic technique

   - Eastern Cooperative Oncology Group performance status less than or equal to 2

Exclusion Criteria:

   - Received prior salvage therapy, including radiotherapy

   - Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not
   completed 4 weeks prior to first dose of study drug

   - Concurrent use of other investigational agents


drug: brentuximab vedotin

drug: bendamustine

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.